Clinical Scorecard: Long-Term Outcomes of Diabetes Remission Following Bariatric Surgery: A Decade of Follow-Up Analysis
At a Glance
Category
Detail
Condition
Type 2 Diabetes Mellitus (T2DM) in patients with obesity
Key Mechanisms
Metabolic and bariatric surgery (MBS) induces weight loss leading to improved glycemic control and potential diabetes remission
Target Population
Adults with T2DM and BMI ≥ 30 kg/m2, specifically those with obesity (BMI ≥ 35 kg/m2) undergoing MBS
Care Setting
Multidisciplinary surgical obesity management centers with long-term follow-up
Key Highlights
MBS leads to diabetes remission in approximately 78% of patients and remission or improvement in 87%.
Durable remission of T2DM can be sustained for at least 10 years post-MBS in a substantial proportion of patients.
Predictors of long-term remission include younger age, shorter diabetes duration, absence of insulin therapy, lower preoperative HbA1c and fasting glucose, and higher C-peptide levels.
Guideline-Based Recommendations
Diagnosis
Diabetes defined by HbA1c ≥ 6.5%, fasting glucose ≥ 126 mg/dL, or treatment with two or more anti-diabetic drugs.
Exclude patients treated exclusively with metformin without diabetes diagnosis due to its use in prediabetes and other conditions.
Management
Recommend MBS for adults with T2DM and BMI ≥ 30 kg/m2 as a weight and glycemic management approach.
Use RYGB or sleeve gastrectomy procedures with standardized limb lengths as surgical options.
Monitoring & Follow-up
Assess metabolic status including body weight, BMI, fasting glucose, HbA1c, lipid panel, blood pressure, and diabetes medication use preoperatively and at 2 and 10 years postoperatively.
Monitor for diabetes remission defined by HbA1c < 5.7% (complete) or 5.7–6.5% (partial) without pharmacologic therapy.
Monitor for diabetes recurrence defined by HbA1c ≥ 6.5% or reintroduction of anti-diabetic medications after remission.
Risks
Potential for diabetes recurrence after initial remission necessitates long-term follow-up.
Re-operative bariatric surgeries excluded due to differing outcomes and complexity.
Patient & Prescribing Data
Patients with obesity and T2DM undergoing MBS with at least 10 years of follow-up data.
Sustained diabetes remission correlates with preoperative clinical factors; pharmacologic therapy can often be discontinued in remission but requires monitoring for relapse.
Clinical Best Practices
Select patients for MBS based on BMI ≥ 30 kg/m2 with T2DM and consider predictors of remission to optimize outcomes.
Use standardized definitions for diabetes remission and recurrence to guide clinical decision-making.
Ensure comprehensive long-term follow-up including metabolic and medication status to detect relapse early.
Exclude patients on metformin monotherapy without diabetes diagnosis to avoid misclassification.
Employ multidisciplinary teams for surgical obesity management to optimize patient care and data collection.
by Inês Meira, João Menino, Patrícia Ferreira, Ana Rita Leite, Juliana Gonçalves, Helena Urbano Ferreira, Sara Ribeiro, Telma Moreno, Diana Festas Silva, Jorge Pedro, Ana Varela, Selma Souto, Paula Freitas, Eduardo Lima da Costa, Joana Queirós, CRIO Group
A pharmacovigilance analysis of FDA adverse event reports finds the strongest ischemic optic neuropathy reporting signal with high-dose semaglutide formulations, with higher adjusted odds reported in men.
These 10 states make it more practical for physicians to participate in hospital ownership by aligning statutory structure, corporate practice of medicine rules, and population trends.
